tbuckley/cabot-search huggingface dataset:
Pulse dose imatinib (Im) and weekly paclitaxel (P) phase I trial for advanced refractory solid tumors
Authors: S. M. Malik, D. J. Moore, J. J. Hwang, A. Bahrani, J. McGreivy, P. Ramzi, M. J. Egorin, F. D. Min, K. McDougall, J. L. Marshall
Journal: Journal of Clinical Oncology (2005)

3118 Background: Imatinib (Im) via PDGFR inhibition decreases the interstitial fluid pressure of tumor, increases cytotoxic drug uptake in preclinical studies, and thus may improve the efficacy of chemotherapy. Im combined with P enhances P activity in severe combined immune deficiency (SCID) mice bearing tumor xenografts. In our initial phase I patient (pt) cohort, neutropenia was the main obstacle in dose escalating daily Im with weekly P. Switching to a 4-d pulse of Im given with weekly P has allowed dose escalation. Methods: 22 pts with advanced refractory solid tumors have been treated to study the toxicities and pharmacokinetics (PK) of the combination of Im and P. Drug doses, schedules and pt numbers are listed below. Pts had received an average of 2.7 (range, 0–5) prior chemotherapy regimens. Results: 19/22 patients completed 2 cycles (C) with 3 PR, 8 SD, and 9 PD. Through 12/2/04, 8 pts completed 4C. 3 have completed 6C with 1 continuing in PR. PRs were noted in colon cancer, esophageal cancer, and leiomyosarcoma. The amended dose levels (DL1A-4A) were generally better tolerated with 9% Gr 3 neutropenia (1/11) for pulse Im versus 45% (5/11) for daily Im. DLTs were 3 pts with Gr 3 fatigue (1 each at DL-1, DL2A, DL3A) and 1 pt with Gr 3 neuropathy previously treated with P and docetaxel. The most common grade 2 or higher adverse effects were fatigue (50%), neutropenia (45%), anemia (32%), allergic reaction to P (23%), and nausea (23%). PK data indicate that P does not exert a substantial effect on Im or its active metabolite, CGP74588. Accrual is ongoing. Conclusion: Neutropenia was the main obstacle in combining daily Im with P even at low doses. Administration of pulse Im with P chemotherapy decreases toxicity, allows for dose escalation and demonstrates significant clinical activity. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Bristol-Myers Squibb, Novartis Bristol-Myers Squibb, Novartis Novartis
Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure
Authors: Tommaso Mauri, Cecilia Turrini, Nilde Eronia, Giacomo Grasselli, Carlo Alberto Volta, Giacomo Bellani, Antonio Pesenti
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

High-flow nasal cannula (HFNC) improves the clinical outcomes of nonintubated patients with acute hypoxemic respiratory failure (AHRF).To assess the effects of HFNC on gas exchange, inspiratory effort, minute ventilation, end-expiratory lung volume, dynamic compliance, and ventilation homogeneity in patients with AHRF.This was a prospective randomized crossover study in nonintubated patients with AHRF with PaO2/setFiO2 less than or equal to 300 mm Hg admitted to the intensive care unit. We randomly applied HFNC set at 40 L/min compared with a standard nonocclusive facial mask at the same clinically set FiO2 (20 min/step).Toward the end of each phase, we measured arterial blood gases, inspiratory effort, and work of breathing by esophageal pressure swings (ΔPes) and pressure time product, and we estimated changes in lung volumes and ventilation homogeneity by electrical impedance tomography. We enrolled 15 patients aged 60 ± 14 years old with PaO2/setFiO2 130 ± 35 mm Hg. Seven (47%) had bilateral lung infiltrates. Compared with the facial mask, HFNC significantly improved oxygenation (P < 0.001) and lowered respiratory rate (P < 0.01), ΔPes (P < 0.01), and pressure time product (P < 0.001). During HFNC, minute ventilation was reduced (P < 0.001) at constant arterial CO2 tension and pH (P = 0.27 and P = 0.23, respectively); end-expiratory lung volume increased (P < 0.001), and tidal volume did not change (P = 0.44); the ratio of tidal volume to ΔPes (an estimate of dynamic lung compliance) increased (P < 0.05); finally, ventilation distribution was more homogeneous (P < 0.01).In patients with AHRF, HFNC exerts multiple physiologic effects including less inspiratory effort and improved lung volume and compliance. These benefits might underlie the clinical efficacy of HFNC.
Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study.
Authors: Antonio Palumbo, Patrizia Falco, Antonietta Falcone, Paolo Corradini, Francesco Di Raimondo, Nicola Giuliani, Giuseppe Rossi, Fortunato Morabito, Letizia Canepa, Alessandro Gozzetti, Maria Teresa Ambrosini, Jerome Zeldis, Robert Knight, Robin Foà, Mario Boccadoro, Maria Teresa Petrucci
Journal: Blood (2006)
Prognostic understanding, quality of life (QOL), and mood in patients undergoing hematopoietic stem cell transplantation (HCT).
Authors: Areej El-Jawahri, Lara Traeger, Justin Eusebio, Kailyn Kuzmuk, Harry Vandusen, Jennifer Shin, Emily R. Gallagher, Joseph A. Greer, William F. Pirl, Karen K. Ballen, Thomas R. Spitzer, Timothy A. Graubert, Steven L. McAfee, Bimalangshu Dey, Vicki A. Jackson, Yi-Bin Albert Chen, Jennifer S. Temel
Journal: Journal of Clinical Oncology (2014)

219 Background: In advanced cancers, patients’ prognostic perceptions influence their medical decisions. However, little is known about how patients with hematologic malignancies undergoing HCT and their family caregivers (FC) understand their prognosis. We examined prognostic perception in these patients during hospitalization for HCT and its relationship with QOL and mood. Methods: We conducted a longitudinal study of patients (and FC) hospitalized for HCT. At baseline (6 days pre-HCT), we used a 10-item questionnaire to measure patients’ and FC information preferences, and perception of prognosis. Using 2-items, we also asked oncologists regarding the patients’ prognosis. At day-6, day+1, day+8 of HCT, we assessed QOL (Functional Assessment of Cancer Therapy-Bone Marrow Transplantation FACT-BMT), and mood (Hospital Anxiety and Depression Scale). We examined the relationship between patients’ prognostic perception and their QOL and mood during hospitalization for HCT using multivariable linear mixed models. Results: We enrolled 97% of consecutively eligible patients undergoing autologous (n=30), myeloablative (n=30) or reduced intensity (n=30) allogeneic HCT. Most patients (80/90, 88.9%) and FC (41/47, 87.1%) believed that it is ‘extremely’ or ‘very’ important to know about prognosis. However, the majority of patients (66/85, 77.6%) and FC (33/46, 71.7%) reported an inaccurate and more optimistic perception of the patients’ prognosis compared to the oncologist (P &lt; 0.0001). Patients with accurate prognostic understanding reported lower QOL (P = 0.03) and worse depressive symptoms (P = 0.04) with a steeper increase in depression (P = 0.006) over time compared to patients with an inaccurate optimistic prognostic perception. Conclusions: The majority of patients and FC reported inaccurate and more optimistic perception of prognosis compared with the oncologist. Patients with an accurate perception of their prognosis had lower QOL, higher depression, and a steeper increase in depression during hospitalization for HCT. Interventions are needed to improve prognostic understanding while providing adequate psychosocial support during HCT.
Retroviral Mediated Transfer of MLL Fusion Genes into Human CD34+ Cord Blood Cells Supports the Establishment of Long-Term Myeloid Cultures with Growth Rates, Immunophenotypic and Transcriptional Features Distinct from Those of AML1-ETO Transduced Cultures.
Authors: Jorge F. DiMartino, Catherine Rettig, Mark Wunderlich, James C. Mulloy
Journal: Blood (2005)
Higher Non-Relapse Mortality with BuCyVP Compared to BuCy In Allogeneic Hematopoietic Stem Cell Transplant
Authors: Hien Duong, Brian J. Bolwell, Lisa Rybicki, Matt Kalaycio, Steven Andresen, Ronald Sobecks, Robert Dean, John William Sweetenham, Shawnda Tench, Edward A. Copelan
Journal: Blood (2010)
Pre-Clinical Characterization of T Cell-Dependent Bispecific Antibody Anti-CD79b/CD3 As a Potential Therapy for B Cell Malignancies
Authors: L. Laura Sun, Xiaocheng Chen, Yvonne Chen, Mark S. Dennis, Diego Ellerman, Clarissa Johnson, Mary Mathieu, Amy Oldendorp, Andrew G. Polson, Arthur Reyes, Eric Stefanich, Hong Wang, Peiyin Wang, Bing Zheng, Allen J. Ebens
Journal: Blood (2014)